Neurocrine Biosciences CEO sells $116,020 in stock

SAN DIEGO—Gano Kyle, the Chief Executive Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently engaged in a series of stock transactions according to a Form 4 filing with the Securities and Exchange Commission. The transactions come as the company’s stock has declined over 22% in the past week, trading near its 52-week low of $110.95.

On February 10, Mr. Kyle sold 980 shares of Neurocrine Biosciences common stock, generating proceeds of approximately $116,020. The shares were sold at a weighted average price of $118.39, with individual sale prices ranging from $116.08 to $123.57. According to InvestingPro data, the company maintains strong financials with a current ratio of 3.4 and operates with moderate debt levels.

Earlier, on February 8, Mr. Kyle acquired 1,860 shares through the vesting of Restricted Stock Units (RSUs), which were granted to him in 2021. These shares were acquired at no cost as part of his compensation package. Following these transactions, Mr. Kyle holds 137,658 shares of the company. Want deeper insights? InvestingPro subscribers have access to 12 additional ProTips and comprehensive analysis for NBIX.

The sales were executed under a pre-established Rule 10b5-1 trading plan, which provides guidelines for insider trading to avoid potential conflicts of interest. The company currently trades at a P/E ratio of 34.5 and has demonstrated strong revenue growth of 24.8% over the last twelve months.

In other recent news, Neurocrine Biosciences has been the subject of several analyst reviews following its reported revenue results and future estimates. Deutsche Bank (ETR:DBKGn) initiated coverage on the company’s stock with a Hold rating and a price target of $138, attributing the rating to the perceived fair valuation of the stock based on its current market capitalization and the performance of its Ingrezza and Crensessity treatments.

UBS, on the other hand, maintained a Buy rating but lowered its price target for Neurocrine Biosciences to $154 from $176. This adjustment was made in light of the recent decline in the company’s shares and the lower-than-expected guidance for Ingrezza. Guggenheim also maintained a Buy rating but reduced its price target to $163 from $165 following the company’s fourth-quarter sales report, which showed slightly lower than expected Ingrezza sales.

H.C. Wainwright continues to recommend the stock as a Buy despite adjusting its price target to $185 from $190. The firm’s decision was influenced by the lower-than-expected full-year 2025 Ingrezza revenue guidance. Finally, Neurocrine Biosciences reported sales of $2 million for its newly launched drug, Crenessity, in the last two weeks of December, which was seen as promising by H.C. Wainwright.

These recent developments highlight the ongoing analyst interest in Neurocrine Biosciences and its financial performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.